CA
MRNA icon

Continuum Advisory’s Moderna MRNA Stock Holding History

Continuum Advisory’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-127
Closed -$3.6K – 1138
2025
Q1 		$3.6K Sell
127
-32
-20% -$1.14K ﹤0.01% 1180
2024
Q4 		$6.61K Sell
159
-1
-0.6% -$48 ﹤0.01% 1080
2024
Q3 		$6.36K Buy
160
+14
+10% +$1.28K ﹤0.01% 1100
2024
Q2 		$17.3K Buy
146
+8
+6% +$1.01K ﹤0.01% 817
2024
Q1 		$16.9K Buy
+138
New +$13.9K ﹤0.01% 812
2023
Q4 		– Sell
-2,206
Closed -$228K – 474
2023
Q3 		$228K Sell
2,206
-215
-9% -$24K 0.04% 404
2023
Q2 		$294K Sell
2,421
-616
-20% -$82.2K 0.05% 369
2023
Q1 		$466K Sell
3,037
-324
-10% -$53.4K 0.08% 270
2022
Q4 		$604K Sell
3,361
-89
-3% -$14.6K 0.11% 223
2022
Q3 		$408K Buy
3,450
+390
+13% +$59.2K 0.07% 272
2022
Q2 		$437K Sell
3,060
-460
-13% -$65.8K 0.08% 273
2022
Q1 		$473K Buy
3,520
+495
+16% +$83.3K 0.09% 250
2021
Q4 		$768K Buy
3,025
+697
+30% +$204K 0.17% 138
2021
Q3 		$896K Buy
2,328
+75
+3% +$27.7K 0.24% 98
2021
Q2 		$529K Buy
2,253
+502
+29% +$89.7K 0.16% 140
2021
Q1 		$280K Buy
+1,751
New +$254K 0.12% 143

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Continuum Advisory's MRNA Position: Q2 2025 in Review

Continuum Advisory sold out of Moderna (MRNA) in Q2 2025, closing a stake of 127 shares — an estimated $3.6K sold.

Continuum Advisory first reported a position in MRNA in Q1 2021 and held it in 16 quarters. The position peaked at $896K in Q3 2021. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • Continuum Advisory reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 127 Moderna shares in Q2 2025, an estimated $3.6K.
  • Continuum Advisory first reported a position in Moderna in Q1 2021 and held it in 16 quarters.
  • Continuum Advisory's Moderna position peaked at $896K in Q3 2021.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.